



## **Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022**

March 3, 2022

### **Nyxoah to Release Full Year 2021 Financial Results on March 24 and Host Conference Call on March 25, 2022**

**Mont-Saint-Guibert, Belgium – March 3, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)** (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the full year 2021 on Thursday, March 24, 2022, after the market close. Company management will host a conference call to discuss financial results on Friday, March 25, 2022, beginning at 2:00pm CET / 8:00am ET.

Investors interested in listening to the conference call may do so by dialing (844) 260-3718 for those in the U.S., 0800 73264 for those in Belgium, or (929) 517-0938 for international callers, followed by Conference ID 3688760. A live and archived webcast of the event will be available on the Company’s investor relations website at <https://investors.nyxoah.com>.

#### **About Nyxoah**

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit <http://www.nyxoah.com/>.

**Caution** – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

#### **Contacts:**

##### **Nyxoah**

Loic Moreau, Chief Financial Officer

[corporate@nyxoah.com](mailto:corporate@nyxoah.com)

+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications

[jeremy.feffer@nyxoah.com](mailto:jeremy.feffer@nyxoah.com)

+1 917 749 1494

#### **Attachment**

- [ENGLISH\\_FY 2021 Earnings Call Save-the-Date\\_FINAL](#)